Media ReleasesImmutep

View All Immutep News

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “theCompany”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected for a poster short talk presentation as part of the high-impact paper presentation program at the American Association for Cancer Research (AACR) Virtual Annual Meeting, scheduled for 27 and 28 April.

For more information, please download the attached PDF.

Download this document